Cigna's Specialty Momentum Supports Q2 Results Despite Pharmacy Headwinds, UBS Says

MT Newswires Live08-01

Cigna Group's (CI) Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.

This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.

Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.

Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.

UBS maintained its buy rating on Cigna stock and its $400 price target.

Price: 282.70, Change: -4.96, Percent Change: -1.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656395108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-01 02:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656395108","market":"us","top_or_hot":-1,"title":"Cigna's Specialty Momentum Supports Q2 Results Despite Pharmacy Headwinds, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Cigna Group's (CI) Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.</p><p>This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.</p><p>Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.</p><p>Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.</p><p>UBS maintained its buy rating on Cigna stock and its $400 price target.</p><p>Price: 282.70, Change: -4.96, Percent Change: -1.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cigna's Specialty Momentum Supports Q2 Results Despite Pharmacy Headwinds, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCigna's Specialty Momentum Supports Q2 Results Despite Pharmacy Headwinds, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-01 02:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cigna Group's (CI) Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.</p><p>This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.</p><p>Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.</p><p>Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.</p><p>UBS maintained its buy rating on Cigna stock and its $400 price target.</p><p>Price: 282.70, Change: -4.96, Percent Change: -1.72</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002270589.USD","symbol_name":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656395108","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656395108","pubTimestamp":1785522923,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cigna Group's  Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.UBS maintained its buy rating on Cigna stock and its $400 price target.Price: 282.70, Change: -4.96, Percent Change: -1.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","CI":"信诺保险","LU0058720904.USD":"联博国际健康护理基金A","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4196":"保健护理服务","BK4588":"碎股","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC"},"translate_title":"瑞银表示，尽管药房面临阻力，Cigna 的专业势头仍支撑了第二季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1},"content_text":"Cigna Group's (CI) Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.UBS maintained its buy rating on Cigna stock and its $400 price target.Price: 282.70, Change: -4.96, Percent Change: -1.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656395108","isCrawlerRequest":true}